Eduardo Oliver, awarded the Young Researcher Award of the Spanish Society of Pharmacology

The researcher of the Carlos III National Center of Cardiovascular Research (CNIC) Eduardo Oliver has been awarded the Young Researcher Award of the Spanish Society of Pharmacology, recognition that this society grants to its members under 35 years of age with the best scientific career. This award has a prize of 1200€, which is to be divided with the other award winner Miguel Romero, from the University of Granada. This award is added to the one received last year by the Federation of European Pharmacological Societies for the publication of the article “The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia” (Nature, 2015; 524:356-360), where he is the main author.

 Eduardo Oliver Perez obtained his degree in Pharmacy at the University of Valencia in 2004 and did his PhD thesis on the role of the adrenergic receptors (alfa 1 and beta), and the kinases that regulate them, in the genesis and maintenance of cardiovascular diseases like high blood pressure, cardiac failure or a heart transplant. During his pre-doctoral period, Eduardo spent a period at the University of Glasgow (United Kingdom), in Professor John McGrath’s laboratory, researching the role of the different subtypes of adrenergic receptors like regulators of expression of other subtypes in different tissues. In January of 2011, after finishing his thesis, he obtained a Postdoctoral contract, associated to a project financed by the British Heart Foundation, to join the research group in Experimental Medicine led by Professor Martin Wilkins and Dr. Lan Zhao at the prestigious university Imperial College London. Thanks to these studies, in August of 2015 he published an article in Nature magazine, as main author, where he describes the search and validation of the zinc transporter ZIP12 as a new therapeutic target. His scientific production is consistent, with 22 publications in high-impact magazines and several communications to national and international congresses.  In addition, his postdoctoral research has given way to a patent about therapeutic applications and the use of the zinc transporter ZIP12 in the treatment of Pulmonary Hypertension